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PENGENALPASTIAN PENANDA-PENANDA BIO BAGI KANSER 
KOLOREKTAL DARIPADA PESAKIT-PESAKIT MALAYSIA 
 
ABSTRAK 
 
Kes-kes kanser kolorektal (CRC) semakin meningkat. Akan tetapi, 
penanda-penanda bio yang dapat menggambarkan perkembangan CRC masih 
kekurangan walaupun kemajuan dalam alat-alatan proteomik dan “microarray” 
telah tercapai. Tujuan kajian ini adalah untuk mengenalpasti penanda-penanda 
bio berpotensi bagi diagnosis CRC dalam kalangan pesakit-pesakit Malaysia. 
Dalam kajian ini, pengekstrakan turutan dijalankan dengan menggunakan larutan 
tampan Tris dan diikuti dengan larutan lisis tiourea (TLB), hal ini adalah untuk 
mengurangkan kerumitan proteom CRC. Tisu-tisu mukosa normal dan kanser 
diperolehi daripada spesimen pembedahan 26 pesakit CRC. Protein-protein yang 
diekstrak dipisahkan oleh elektroforesis gel dwi-dimensi. Tompok protein-protein 
yang diekspres pada kadar yang berbeza dipencilkan untuk analisis 
pengenalpastian protein oleh kromatografi cecair tandam spektrometri jisim (LC-
MS/MS). Kami telah mengenalpasti 37 protein hidrofilik dalam ekstrak Tris dan 
24 protein hidrofobik dalam ekstrak TLB daripada sampel-sampel yang dikumpul. 
Leukocyte elastase inhibitor (LEI) dan 60 kDa heat shock protein (HSP60) 
xxvi 
 
merupakan penanda bio yang berpotensi untuk CRC dalam ekstrak Tris manakala 
triosephosphate isomarase (TPI) dan annexin A3 merupakan penanda bio yang 
berpotensi bagi CRC dalam ekstrak TLB. Di samping itu, LEI ialah penanda bio 
berpotensi bagi pesakit CRC pada peringkat III yang berkombinasi dengan 
adenokarsinoma pembezaan sederhana (MDA), adenokarsinoma pembezaan baik 
(WDA) ataupun metastasis nodus limfa. Fibrinogen beta chain (FIBB) 
merupakan penanda bio yang baik bagi pesakit-pesakit CRC peringkat II dan 
MDA.  Kami juga menemui corak ekspresi protein yang khusus dalam kalangan 
ketiga-tiga bangsa. TPI dikenalpasti sebagai penanda bio yang berpotensi bagi 
pesakit CRC pada peringkat III yang berkombinasi dengan WDA, MDA ataupun 
metastasis nodus limfa. Tisu-tisu CRC peringkat II dan MDA menunjukkan 
bahawa annexin A3 ialah penanda bio yang berguna. TPI dan annexin A3 
diekspres secara umum dalam ketiga-tiga bangsa (Cina, Melayu dan India), hal 
ini mencerminkan kepentingan penanda-penanda bio ini dalam kalangan pesakit 
Malaysia. Keputusan pewarnaan-imun pada calreticulin dan heat shock 70 kDa 
protein (HSP70) pada sel HT29 dan HCT116 menunjukkan kedua-dua protein 
tersebut terletak pada permukaan luar membran sel. Analisis komponen utama 
(PCA) dan analisis pembezalayan linear (LDA) mencerminkan kenyataan 
protein-protein yang diekspres dalam kadar berbeza untuk menggambarkan 
keadaan kanser dalam tisu-tisu. 
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IDENTIFICATION OF BIOMARKERS FOR COLORECTAL CANCER FROM 
MALAYSIAN PATIENTS 
 
ABSTRACT 
 
Colorectal cancer (CRC) is on the rise. However, biomarkers for 
indication of CRC progression is still lacking despite several advances in 
proteomic and microarray tools.  This study aims to identify potential biomarkers 
for the diagnosis of CRC among Malaysian patients. In this study, sequential 
extraction was first performed using Tris buffer followed by TLB buffer in order 
to reduce the complexity of the CRC proteome. The tissues used were surgical 
resections of normal mucosa and cancerous tissues from 26 CRC patients. The 
extracted proteins were separated by 2D gel electrophoresis. The differentially 
expressed protein spots were then mapped for further protein identification by the 
use of liquid chromatography tandem mass spectrometry (LC-MS/MS). We have 
identified 37 hydrophilic proteins in the Tris extracts and 24 hydrophobic 
proteins in the thiourea lysis buffer (TLB) extracts from the samples collected. 
Leukocyte elastase inhibitor (LEI) and 60 kDa heat shock protein (HSP60) were 
the potential biomarkers for CRC analyzed from the Tris extracts whereas 
triosephosphate isomerase (TPI) and annexin A3 were the potential biomarkers 
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for CRC analyzed from the TLB extracts. Moreover, LEI was the potential 
biomarker for CRC patients at stage III in combination with either moderately 
differentiated adenocarcinoma (MDA), well differentiated adenocarcinoma 
(WDA) or lymph node metastasis CRC. Fibrinogen beta chain (FIBB) was a 
good biomarker in CRC patients at stage II and MDA. We also noted distinctive 
protein expression patterns among the three races. TPI was the potential 
biomarker in CRC patients at stage III in combination either with MDA, WDA or 
lymph node metastasis CRC. Stage II and MDA CRC tissues revealed annexin 
A3 as a useful biomarker. TPI and annexin A3 were found commonly expressed 
in the three races (Chinese, Malay and Indian), reflecting the importance of these 
biomarkers in CRC amongst Malaysian patients. Immunostaining results of 
calreticulin and heat shock 70 kDa protein (HSP70) on HT29 and HCT116 colon 
cell lines revealed the cellular location of these proteins on the external surface of 
cell membranes. Principal component analysis (PCA) and linear discriminant 
analysis (LDA) reflected the significance of these differentially expressed 
proteins in indicating the state of cancer in tissues. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cancer 
Cancer is a complex and unpredictable genetic disorder (Cornelisse, 
2003) which causes abnormal growth of cells. It is the result of the accumulation 
of genetic mutations that allows tumour cells to grow. Cancer is characterized by 
uncontrolled cell proliferation, division and disruption between apoptosis by loss 
of cell cycle control, sustained angiogenesis and increase of cell ability to invade 
other tissues and metastasize (Hanahan and Weinberg, 2000; Søreide et al. 2006). 
Today, cancer is one of the main causes of global mortality. 
 
1.1.1 Carcinogenesis 
Carcinogenesis is a multi-step progression of cancer development. It is 
divided into three main stages; initiation, promotion and progression (Chu et al., 
2007). In the initiation stage, normal cells are exposed to carcinogens for a period 
of time, which causes damage to their genetic information and predisposes them 
to become cancerous. In colorectal cancer, the carcinogenic agents include 
tobacco, alcohol and diet. However, the initiated cells usually do not immediately 
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become cancerous. In the promotion stage, the initiated cells are induced to grow 
and divide rapidly due to exposure to promoting agents that disrupt cells’ normal 
growth cycle. In the progression stage, the cells will undergo further 
transformations which will result in autonomous growth and division, and 
become more aggressive. These cancerous cells will be able to grow and divide 
rapidly and spread to other parts of the body.  
 
1.1.2 Metastasis 
Metastasis is the process when cancer cells travel from the primary site 
(organ or tissue) to other parts of the body, where they influence the secondary 
site to divide abnormally. Cancer cells that metastasize exhibit several 
characteristics; they have the capability to invade, enter and exit the vasculature, 
deregulated adhesion, avoid being killed by immune cells and escape anoikis, 
which is the programmed cell death that is caused by the loss of cell matrix 
interaction (Stein and Schlag, 2007). Metastasis is the major cause of death in 
cancer. 
The metastatic cascade occurs in several steps. Firstly, the cancer cell 
detaches itself from the primary mass by loss of adhesion and proteolysis of the 
extra-cellular matrix (ECM). The cancer cell then migrates through the 
intracellular space to reach the blood or lymphatic vessels. They invade the vessel 
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walls (intravasation) and enter the blood circulation. When the cell arrives at a 
distant site, they arrest in the capillary beds, breach the vessel wall again and 
adhere to secondary sites (extravasation). There, they will proliferate at the new 
site (Stein and Schlag, 2007). The metastatic cascade model is shown in Figure 
1.1. 
 
Figure 1.1 Model for the metastatic cascade of colorectal cancer metastasis 
(Stein and Schlag, 2007). 
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1.2 Colon and Rectum 
The colon and rectum form the lower part of the human gastrointestinal 
tract. They consist of the caecum, ascending, transverse, descending colon, 
sigmoid colon, rectum and appendix. Colorectum, also known as the large 
intestine or large bowel, is a 5 feet long muscular segment. The colon serves to 
absorb water and nutrients from partially digested foods that enter into the colon 
from the small intestine. The caecum is located in the beginning of the large 
intestine and joins to the ascending colon on the right side of the abdomen. At 
one point, the hepatic flexure turns towards the midline to form the transverse 
colon. The transverse colon across the spleen turns downward at the splenix 
flexure. At the left side of the abdomen, the descending colon turns into S-shape 
sigmoid colon. The rectum is the last section of large intestine, passing the waste 
(stool) out from the body. It connects the end of the sigmoid colon to the anus. 
There are four layers of tissues that make up the colon; mucosa, submucosa, 
muscularis, and serosa. The muscularis is further divided into muscularis mucosa 
that is located between the mucosal and submucosal layers, while the muscularis 
propria is located in the middle of submucosal and serosa (John Hopkins 
Medicine, 2010). Colon cells reproduce in the crypts of Lieberkuhn found in the 
mucosal layer. When new cells are generated, the old matured colon cells tend to 
migrate out from the crypts and die off. Any damages to the crypt could bring 
harm to the cells and cause the formation of adenomas (Griffin-Sobel, 2001). 
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During a lifetime, colon cells may transform, leading to colorectal carcinoma. 
The anatomy of the colon is shown in Figure 1.2 (John Hopkins Medicine, 2010). 
 
Figure 1.2 Anatomy of the colon and rectum (John Hopkins Medicine, 2010). 
 
1.3 Colorectal Cancer 
Colorectal cancer (CRC) includes the cancer of the colon, rectum and 
appendix. The mechanism of how CRC developed has yet to be understood, 
however, it is possible that an adenomatous polyp grows on the mucosal 
epithelium, the polyp slowly develops into colorectal carcinoma (Griffin-Sobel, 
2001). Individuals with a family history of colon cancer or have inflammatory 
bowel disease, or cancer in the uterine, ovarian, ureter or bladder have a higher 
risk of getting colorectal cancer (Sweed and Meropol, 2001). Inherited syndrome, 
environmental factors, sedentary lifestyle (alcohol consumption and smoking) 
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and diet (low folate and fibre intake, high fat, red meat consumption) also 
increase the chance of developing colorectal cancer (Willett, 2001). Patients 
suffering from inflammatory bowel disease have a tenfold risk of developing 
CRC. Those with a family history of CRC, including their first degree relatives 
have an increased risk of contracting CRC. Patients that carry hereditary 
conditions such as Familial Adenomatous Polyposis or Hereditary Non Polyposis 
Colorectal Cancer have a higher risk of developing colorectal cancer.  
Early colorectal cancer is usually asymptomic. In early stages, an unusual 
or continuing fatigue, weight loss will be experienced by the patient. When the 
tumours are in an advanced state, symptoms such as abdominal pain, diarrhea, 
and changes in bowel movement and blood in stool can be clearly observed in 
CRC (Sweed and Meropol, 2001). 
Screening and surveillance of CRC substantially reduce both the 
incidence and mortality of CRC (Harford, 2006). CRC screening for individuals 
is recommended at the age of 50. Screening of CRC in normal-risk individuals 
can be done by several methods; faecal occult blood test (FOBT), colonoscopy, 
sigmoidoscopy, double contrast barium enema and digital rectal exam. Newer 
technologies for screening CRC include virtual colonoscopy, faecal 
immunochemical testing for blood and faecal DNA testing. 
The treatment of CRC depends on the location of the tumour and stage of 
the disease. Colon and rectal cancer diagnosed at an early stage is treated by 
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surgical removal of the involved colon. Radiotherapy, chemotherapy and targeted 
therapy may also apply to the metastatic colorectal cancer. 
Adenocarcinoma is the most common type of colorectal cancer 
(American Cancer Society, 2010a). Other histological types include adenoma in 
situ, mucinous carcinoma, signet ring carcinoma, squamous cell (epidermoid) 
carcinoma, adenosquamous carcinoma, small cell carcinoma, undifferentiated 
carcinoma and carcinoma. Tumours in the ascending colon resemble cauliflower-
like fungating masses that become ulcerative and necrotic. These tumours are 
usually well-differentiated. However, tumours in the descending and sigmoid 
colon are ulcerative and are likely to penetrate the bowel wall. Rectosigmoid 
tumours occur as villous or frondlike lesions (Griffin-Sobel, 2001). 
 
1.3.1 Incidence of Colorectal Cancer 
CRC is the third most common cancer in the world, accounting for 8.6% 
of deaths worldwide. CRC is the fourth most frequent type of cancer affecting 
both males and females in the world (World Health Organization, 2009). The 
estimated incidence and estimated deaths each year from CRC is approximately 
1.16 million and 630,000, respectively (Garcia et al., 2007). In Malaysia, CRC 
was responsible for 14.2% of male cancers and 10.1% of female cancers, making 
it the most common cancer among men and the third most common cancer 
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among women (Lim and Halimah, 2004). In 2003, 1335 cases of CRC in males 
and 1217 cases of CRC in females were reported. CRC is the third most common 
cause of cancer-related death in Malaysia and the Chinese have the highest 
incidence of CRC (Malaysian Oncological Society, 1999; Lim and Halimah, 
2004). 
 
1.3.2 Colorectal Carcinogenesis 
Colorectal cancer (CRC) is a well studied cancer model (Schulmann et 
al., 2002), a small lesion slowly develops into premalignant lesions and to 
invasive cancer over years.  This progression is caused by genetic changes, such 
as activation of protooncogenes and inactivation of tumour suppressor genes, 
which result in tumorigenesis in CRC. These molecular events are described in 
the colon cancer adenoma-carcinoma sequence model by Fearon and Vogelstein 
(1990). Two distinct pathways have been identified; the microsatellite instability 
(MSI) and the chromosomal instability pathways (CIN). 
Adenoma-carcinoma sequence represents the stepwise progression from 
early lesions to carcinomas in a linear way (Stein and Schlag, 2007). This 
sequence is displayed in Figure 1.3. CRC is initiated by the growth of benign 
polyps. Polyps refer to a mass of cells that grow above the surface of surrounding 
normal mucosa. Inactivation of both alleles of the APC gene located on 
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chromosome 5 and activation of mutations in the β-catenin gene cause the onset 
of colorectal tumorigenesis. This is followed by the activation of the K-ras 
protooncogene through mutation of codon 12 or 13. The progression from 
adenoma to intermediate adenoma and then to carcinoma involves the loss of 
heterozygosity (LOH) of the long arm of chromosome 18q, near the SMAD4 
(DPC4) locus. In addition, mutations in DCC and SMAD2 tumour suppressor 
genes may also be involved. At the late stage of tumorigenesis, mutation of p53 
on chromosome 17p occurs, which is thought to allow tumour growth to evade 
cell cycle arrest and apoptosis. Mutation of DNA mismatch repair genes, 
including hMSH2, hMLH1, hPMS1 or hPMS2 also plays a role in CRC 
formation (Tejpar and van Cutsem, 2002; Stein and Schlag, 2007).   
 
 
 
 
 
 
Figure 1.3 Adenoma-carcinoma sequence model of colorectal cancer (Stein 
and Schlag, 2007). 
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Colorectal polyps can be either neoplastic (adenomatous) or non-
neoplastic (hyperplastic and hamartomous) (Schulmann et al., 2002). In most 
cases, adenoma polyp remain benign and asymptomic lesions under endoscopy. 
However, these small lesions may evolve into malignancy and there are 
evidences indicating that the majority of colorectal carcinomas develop from 
adenomatous polyps (Konishi and Morson, 1982). Hamartomatous polyps have 
lower tendencies to malignant transformation whereas hyperplastic polyps are 
free from the risk.  Adenomatous polyps are precursors of colorectal cancer 
(Muto et al., 1975). The evidence of adenoma progress to adenocarcinomas 
supports the practice of removing adenomatous polyps to reduce and prevent 
colorectal cancer incidence (Winawer, et al., 1993).  
 
1.3.3 Colorectal Cancer Classification 
Colorectal cancer is classified into three main groups; sporadic, 
hereditary and familial cancer, with each interposing specific clinical features.   
 
1.3.4 Sporadic Colorectal Cancer 
Sporadic colorectal cancer is the common type of CRC, accounting for 
75% of all CRC cases. Sporadic CRC is a cancer with no apparent hereditary 
symptoms, where the patient has no prior family history of CRC (John Hopkins 
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Medicine, 2010).  Sporadic CRC arises from the expansion of a subset of cells 
that have acquired a growth advantage through randomly acquired somatic 
mutations (Søreide et al., 2009). The chances of developing sporadic CRC 
increases with age, the average lifetime risk of getting sporadic CRC after 50 
years old is 5% (Schulmann et al., 2002). This is consistent with the theory that 
cells must accumulate genetic defects, including gene mutations to undergo full 
transformation from normal to cancerous. Individuals that have one or more 
adenomas have a 45% chance of getting sporadic CRC.  The size of these 
adenomas is 4-5 mm, and the chances for any adenoma to develop into cancer are 
1 in 400 per year. However, if the size of adenomas is larger, the risk increases to 
1 in 4 per year. Those with affected first-degree relatives have a higher risk of 
developing CRC (Chu et al., 2007). Symptoms of sporadic CRC include 
abdominal pain, change in bowel habits and rectal bleeding. 
 
1.3.5 Hereditary Colorectal Cancer 
Hereditary colorectal cancer is a form of CRC where the gene that causes 
CRC in the family is known. Hereditary CRC makes up 10% of all CRC cases. 
Hereditary CRC is associated with a germline mutation in a known cancer 
susceptibility gene. If a person inherited a cancer susceptibility gene from a 
parent who has a family history of CRC, the person is predisposed to develop 
CRC. There are two groups of hereditary colorectal cancers; the polyposis 
12 
 
syndromes with multiple colorectal polyps and the non-polyposis syndromes with 
only one or a few polyps. The polyposis syndromes include familial adenomatous 
polyposis (FAP), Peutz-Jeghers syndromes and juvenile polyposis coli. The non-
polyposis syndrome is then divided into hereditary non-polyposis colorectal 
cancer (HNPCC) and familial colorectal cancers with unknown genes (Tonelli, 
2002).  
 
1.3.6 Familial Adenomatous Polyposis 
Familial adenomatous polyposis (FAP) is a disorder that leads to the 
formation of hundreds or thousands of benign adomatous polyps in the colon and 
rectum at a young age, usually as a teenager or young adult. Some of these polyps 
will progress into invasiveness and ultimately metastasize. FAP was the first 
polyposis syndrome to be recognized and therefore remains the best 
characterized.  FAP is an autosomal dominant disease caused by the mutation of 
the APC gene, accounting for 1% of all CRC cases. It has been shown that the 
APC gene is not only responsible for sporadic CRC but also FAP. FAP is 
inherited and primarily affects the colon and less often the stomach and small 
intestine. 
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1.3.7 Hereditary Nonpolyposis Colorectal Carcinoma 
Hereditary nonpolyposis colorectal carcinoma (HNPCC) or known as 
Lynch syndrome is the most common hereditary CRC. HNPCC is an autosomal 
dominant disease and is responsible for 1-6% of all CRC cases (Søreide et al. 
2009). HNPCC is characterized by the development of CRC and endometrial 
cancer at an early age. HNPCC is caused by the mutation in the hMLH1 and 
hMSH2 genes, which when function normally would protect against CRC. 
HNPCC commonly develops in the right side of the colon and is undifferentiated, 
with the presence of mucus and signet ring cells, infilitration of peritumoral 
lymphocyte, Crohn-like reaction and lymphocyte infiltration (Coura et al., 2005). 
Incidence of HNPCC among the population is about 1:1000 in the United States 
(Umar et al., 2004). The diagnosis of HNPCC is based on Amsterdam criteria 
and Bethesda guidelines as HNPCC does not have any apparent phenotypic signs. 
Figure 1.4 shows the different types of colorectal cancers and their distribution. 
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Figure 1.4 Distribution of different types of colorectal cancers (Card and 
Logan, 2003). 
 
1.3.8 Familial Clustering 
Familial clustering of CRC accounts for about 15% of all CRC cases is 
suspected when ―familial accumulation‖ of CRC cases occurs (Lynch et al., 
2006). Firstly, there is an excess number of CRC cases in a family that would be 
statistically expected. The occurrence of CRC in more than one family member 
may be due to chance alone. But it could also mean the potential for developing 
CRC has been inherited from one generation of the family to the next. Relatives 
of a person with CRC in the same family have a higher chance of getting CRC 
themselves. Secondly, the family does not meet the criteria for either sporadic or 
hereditary CRC. The transmission pattern of familial clustering of CRC is not 
75%
% 
5% 
Familial 
clustering 15% 
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understood and does not show any specific inheritance pattern (Susser and 
Susser, 1989). The exact gene that causes this type of cancer is still unknown. 
Relatives of a person with colorectal cancer are more likely to develop CRC 
(Sork, 2008). 
 
1.3.9 Staging of Cancer 
 The cancer stage is the extent of cancer spread in the body (American 
Cancer Society, 2010b).  The stage of colorectal cancer is based on how far the 
cancer cells have grown into the intestinal wall and whether or not they have 
spread to nearby structures, such as lymph nodes or distant organs (American 
Cancer Society, 2010b). The staging process is to determine how extensive a 
cancer has spread and is based on results of the physical examination, biopsies, 
and imaging tests. 
 The Dukes’ classification system was used for early stages of colorectal 
cancer, where the invasion of tumour is limited to mucosa or submucosa. This 
Dukes’ category includes all tumour confined to the bowel wall using an A, B, C 
and D system (Dukes, 1932). This is shown in Table 1.1. 
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Table 1.1 Dukes’ classification of colorectal cancer (Dukes, 1932). 
Duke System Description 
A Penetration into but not through the bowel wall 
B Penetration through the bowel wall 
C Involvement of regional lymph nodes 
D Distant metastasis 
 
 Later, the American Cancer Society defined the stage of colorectal cancer 
by the depth of tumour invasion into the intestinal wall, involvement of lymph 
nodes or distant metastasis (American Cancer Society, 2010b). More recently, 
many modifications of the Dukes’ scheme have been adopted to provide better 
information on prognosis and pattern of the disease. The tumour-node-metastasis 
(TNM) classification is used for colorectal tumour staging. In 2002, the American 
Joint Cancer Committee on Cancer (AJCC) has further grouped the stages II and 
III of colorectal cancer according to tumour size. The higher the stage, the bigger 
the tumour size is. The new staging system for colon cancer stratifies stage II and 
stage III further by use of the T stage (tumour depth of penetration), and the N 
stage (number of positive lymph nodes), resulting in a total of seven stages 
(O’Connell et al., 2004) as shown in Table 1.2.  
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Table 1.2 Guidelines for Dukes’ and TNM Staging System (American Joint 
Committee on Cancer, 2002; O’Connell et al., 2004). 
Dukes’ 
Classification 
Stage 
system 
T 
stage 
N 
stage 
M 
stage 
- 0 Tis N0 M0 
A I T1 or T2 N0 M0 
B IIA T3 N0 M0 
B IIB T4 N0 M0 
C IIIA T1-T2 N1 M0 
C IIIB T3-T4 N1 M0 
C IIIC Any T N2 M0 
D lV Any T Any N M1 
 
 The layers of the colon and the tumour penetration in colorectal cancer 
are shown in Figure 1.5.  
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Figure 1.5 Layers of the colon noting tumour penetration (Griffin-Sobel, 
2001). 
 
 The TNM staging system describes the extent of colorectal cancer into 
several terms; 
Primary Tumor (T) 
Tis Carcinoma in situ, intraepithelial or invasion of the lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscalaris propria 
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T3  Tumor invades muscalaris propria into subserosa, or into 
nonperitonealized or perirectal tissues 
T4   Tumor directly invades other organs or structures, and/or perforates 
visceral peritoneum 
Regional Nodes (N) 
N0 No regional lymph node metastasis 
N1 Metastasis to one to three regional lymph nodes 
N2 Metastasis to four or more regional lymph nodes 
Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
1.3.10 Grading of Cancer 
 Grading determines how similar a cancerous colorectal tissue is to a 
normal colorectal tissue when viewed under a microscope. It also determines how 
aggressive it is for the tumour to grow and spread. The grading scale for 
colorectal cancer ranges from G1 to G4 (National Cancer Institute, 2004; 
American Cancer Society, 2010b). 
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G1 Well differentiated tissue. Cells have the appearance of normal cells, and 
tend grow slowly. The least aggressive type of tumour. 
G2 Moderately differentiated tissue. Cells have an appearance that is less 
like normal cells and often grow faster than G1 cancer cells. More 
aggressive than G1. 
G3 Poorly differentiated tissue. Cells are the least like normal cells. They 
grow more rapidly and are highly aggressive, often spreading into the 
lymph nodes and bone. 
G4  Undifferentiated tissue. 
 
1.4 Biomarker  
 Biomarkers are substances or molecules in a biological system that 
responds to the change of the system. They can be measured and evaluated to 
determine the physiological and pathological changes in a normal condition or 
disease. (Atkinson et al., 2001) The ability of biomarker to be used as an 
indicator helps to monitor disease conditions and assists in its diagnosis and 
prognosis.  
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1.4.1 Cancer Biomarkers 
 The progress of identification of protein biomarkers involves separation 
and analysis of protein samples from individual with and without a particular 
disease. Historical studies revealed the presence of these biomarkers especially in 
the malignancies of gastrointestinal system. One of the examples is 
carcinoembryonic antigen (CEA), discovered in human colon cancer tissue 
extracts that was found to be elevated in the serum of patients with 
gastrointestinal tumors (Gold and Freedman, 1965). Another glycoprotein, 
carbohydrate antigen 19-9 (CA 19-9), originated from patients with colon and 
pancreatic cancer, it was found highly expressed in the serum of patients with 
pancreaticobiliary tumours (Morris-Stiff et al., 2009). Finally, alpha fetoprotein is 
commonly expressed in the serum of patients with hepatocellular cancer (Zhou et 
al., 2006). 
 Although the clinical practice of CRC screening using fecal occult blood 
test (FOBT) and colonoscopy reduces mortality; however, to the best currently 
available blood test, carcinoembryonic antigen exhibits low sensitivity and 
specificity particularly in the setting of early disease. Most of the carcinoma 
(70%) is often diagnosed at late stage and showed poor prognosis (Habermann et 
al., 2008). With the recently advancement of proteomic tools, it is now possible 
to identify CRC biomarkers from the biological matrices, such as serum, tissue or 
cell lines (Jimenez et al., 2010). 
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1.5 Proteomics 
 Proteomics is a study of total protein expression in a living system or 
cell. Proteomics has wide applications in the field of biomedicine for the 
identification of new markers, therapeutic targets and markers of therapeutic 
response (Cole et al., 2000; Minowa et al., 2000). Analysis of the genome and 
transcriptome may provide information on important proteins in the development 
of disease. However, proteome analysis is the most accurate reflection of protein 
expression. The expression of a certain gene caused by alternative splicing of the 
mRNA, posttranslational modifications, temporal and functional regulation may 
not correlate with its corresponding protein (Greenbaum et al., 2003). 
Nevertheless, proteomics is an unbiased approach to examine proteins in complex 
biological fluids, serum as well as tissues from patients. Body fluids, for example 
nipple fluid aspirates, cerebrospinal fluid (CSF) and synovial fluid have been 
applied in the search of biomarkers for various diseases. Blood and urine are 
other specimens that were used to locate candidate biomarkers for clinical 
diagnosis and treatment of diseases (Reichelt et al., 2006; Li, et al., 2007). 
 Basically, proteomics can be grouped into four applications; Global 
proteome mining, protein expression profiling, protein-protein interactions 
identification and posttranslational modification profiling. Global proteome 
mining is the process of identifying all proteins in a sample. Protein expression 
profiling detects and measures differences in protein expression that are 
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characteristic of a particular state of the organism. Protein-protein interactions 
identification is used to determine the condition and manner in which proteins 
interact with each other in a living organism. Posttranslational modification 
profiling establishes how, when and where proteins are modified after their 
synthesis (Liebler, 2002; Simpson, 2003a; Somiari, 2005). Conventional 
proteomic analyses utilized tools based on two-dimensional polyacrylamide 
electrophoresis (2D-PAGE) and mass spectrometry for protein separation, 
analysis and identification. 
 
1.5.1 Electrophoresis 
 Electrophoresis refers to the movement of charged particles or molecules 
under the influence of an electric field. Separation of proteins by means of 
electrophoresis depends on size, charge, shape, temperature and gel medium 
viscosity. Protein’s molecular weight (MW) and isoelectric point (pI) can be 
determined by using electrophoresis separation (Nelson and Cox, 2005). 
Polyacrylamide gel electrophoresis (PAGE) is a widely used matrix for protein 
separation. PAGE with its small pore size acts as molecular sieve and is suitable 
to separate proteins according to shape, size and charge density. Gel matrix 
formation is through free vinyl polymerization of acrylamide monomers. 
Ammonium persulfate (APS) was used to initiate the polymerization process by 
producing free persulfate radicals that convert the acrylamide monomer to a free 
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radical state.  This free radical acrylamide then reacts with other acrylamide 
monomers to form polymers. N,N,N’,N’-tetramethylenediamine (TEMED) is 
added to accelerate the polymerization process The elongating polymers are 
crosslinked with bisacrylamide to form a matrix with a pore size that is 
influenced by the acrylamide/bisacrylamide monomer concentration (Hames, 
1981). PAGE serves as the support matrix in isoelectric focusing (IEF) and 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
  
1.5.2 2D Gel Electrophoresis 
 Two-dimensional (2D) gel electrophoresis is used to separate complex 
protein mixtures. It separates proteins according to the MW and pI. The first 
dimension of protein separation by 2D electrophoresis is by isoelectric focusing 
(IEF). IEF separates proteins based on their isoelectric point (pI). Proteins in 
solution exist as amphoteric molecules. They have a net positive, negative or zero 
charge depending on the surrounding pH. The specific pH where the protein has 
zero net charge is known as its pI (Stochaj et al., 2003). In a pH gradient under an 
electric field, protein moves to a position where its net charge is zero. When a 
protein with positive charge migrates to the cathode, it becomes less charged until 
it reaches its pI where it receives no net charge and therefore stops migrating 
(Garfin and Heerdt, 2000; Berkelman and Stenstedt, 2002; Stochaj et al., 2003). 
The resolution of IEF depends on the pH gradient slope and voltage applied 
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(Berkelman and Stenstedt, 2002). Originally, the IEF was based on carrier 
ampholyte-generated pH gradients in polyacrylamide gel rods in tubes (Klose, 
1975; O’Farrell, 1975). Since then, many improvements focus on reproducibility 
of 2D pattern, because of limitation of carrier ampholytes to generate stable pH 
gradient. These issues were overcome when Gasparic et al. (1975) developed 
immobilized pH gradients (IPG) to form a stable pH gradient within the gel 
matrix. The concept was further expanded until IPG strips were designed by 
Bjellqvist et al. (1982). IPG strip was rehydrated with protein in rehydration 
buffer until swollen before IEF was carried out. 
 
1.5.3 Equilibration  
 The equilibration step on IPG strips was used to transfer proteins from 
first to second dimension. It was first introduced by Görg et al. in 1987. The step 
is essential to let IPG strips be equilibrated after IEF in equilibration buffer. 
Equilibration buffer contains urea (6M), glycerol (30%), SDS (2%), Tris-HCl 
buffer and dithiothreltol (DTT). Urea and glycerol reduce the effects of 
electroendosmosis by increasing the viscosity of the buffer. They also improve 
the transfer of protein from the first to second dimension. Tris-HCl buffer 
maintains the IPG strip and the correct pH for electrophoresis. SDS denatures and 
unfolds proteins to their linear form and confers uniform negative charge to them. 
DTT is a reducing agent to break disulfide bonds to keep the proteins in their 
